Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1138-1143

  Strumberg, Dirk ^a   Schultheis, Beate ^a   Scheulen, M E ^b   Hilger, R A ^b   Krauss, J ^b,h   Marschner, N ^c   Lordick, F ^d,i   Bach, F ^e   Reuter, D ^e   Edler, L ^f   Mross, K ^g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Onkologische Schwerpunktpraxis Freiburg   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e ONCOSCIENCE AG   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

Advanced disease; Clinical trial; EGFR antibody; Nimotuzumab; Pancreatic cancer

Indexed keywords

NIMOTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CHILL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRESS SYNDROME; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL OBSTRUCTION; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VASCULAR DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84864375346     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9619-8     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049-1057 (Pubitemid 38410779)
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
5. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385 (Pubitemid 44142736)
6. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO (2007) Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109:1561-1569 (Pubitemid 46595692)
7. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117:2051-2058 (Pubitemid 47224766)
8. Friedlander E, Barok M, Szollosi J, Vereb G (2008) ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 116:126-140
9. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, Krengel U, Moreno E (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69:5851-5859
10. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 101:567-575
11. Bier H, Hoffmann T, Haas I, van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167-173 (Pubitemid 28239882)
12. Diaz MA, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, Montero E (2007) Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 26:423-431
13. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090-5101 (Pubitemid 32681540)
14. Allan DG (2005) Nimotuzumab: evidence of clinical benefit withoutrash. Oncologist 10:760-761 (Pubitemid 41567290)
15. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radio-therapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646-1654 (Pubitemid 41079803)
16. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeno M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J (2010) Pharmacodynamic trial ofnimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16:2474-2482
17. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Perez R, Lage A (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5:375-379
18. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G (2007) Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25:2006
19. Gounaris I, Zaki K, Corrie P (2010) Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP 11:113-123
20. Petrelli F, Borgonovo K, Ghilardi M, Cabiddu M, Barni S (2010) What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev Recent Clin Trials 5:43-56
21. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Riess H, Oettle H (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. final results of the CONKO 003 study. J Clin Oncol 26 (May 20 suppl):abstr 4508.
22. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R (1997) Humanization ofamouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 3:71-81 (Pubitemid 27197395)
23. Boland WK, Bebb G (2009) Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 9:1199-1206
24. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98:749-755 (Pubitemid 351272610)
25. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R (2008) Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 47:9-19
26. Astsaturov I, Cohen RB, Harari P (2007) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7:650-665 (Pubitemid 350074968)
27. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H (2008) EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 17:1517-1531
28. Tikhomirov IA, Garrido G, Yang E, Sherman I, Pérez R (2008) Bivalent binding properties of epidermal growth factor receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profiles. AACR Cancer Clinical Trials and Personalized Medicine (abstract A36).: Available from: http://www.ymbiosciences.com/upload-files/poster-nimo-AACR- Translational-Med-2008.pdf
29. Garrido G, Rabasa A, Gracia E, Tikhomirov I, Crombet-Ramos T, Viloria-Petit A, Kerbel RS, Yang E, Perez R (2009) Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells. AACR 100th Annual Meeting (abstract 2763): Available from: http://www. ymbiosciences.com/upload-files/nimo-poster-AACR2009. pdf
30. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)